Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada.

ABSTRACT:

Background

In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR status. The purpose of this study is to characterise the use of second or later-line erlotinib therapy in Ontario, Canada from 2007-2016, as well as evaluate the impact of erlotinib therapy on survival and emergency department (ED) visits in a real-world population.

Methods

This is a retrospective cohort study derived at ICES (formerly known as the Institute for Clinical and Evaluative Sciences) of advanced NSCLC patients diagnosed from 2007-2016 in Ontario, Canada, over the age of 65, who received at least one dose of first-line chemotherapy. The exposure of interest was receipt of second or later-

SUBMITTER: Perdrizet K 

PROVIDER: S-EPMC8482335 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature